Summit Creek Advisors LLC raised its stake in Inogen Inc (NASDAQ:INGN) by 133.9% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 138,660 shares of the medical technology company’s stock after purchasing an additional 79,380 shares during the quarter. Summit Creek Advisors LLC owned 0.63% of Inogen worth $9,257,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the business. William Blair Investment Management LLC lifted its holdings in shares of Inogen by 62.2% in the 1st quarter. William Blair Investment Management LLC now owns 1,048,413 shares of the medical technology company’s stock valued at $99,987,000 after buying an additional 402,150 shares during the period. Janus Henderson Group PLC lifted its holdings in shares of Inogen by 15,943.5% in the 1st quarter. Janus Henderson Group PLC now owns 552,056 shares of the medical technology company’s stock valued at $52,650,000 after buying an additional 548,615 shares during the period. Norges Bank acquired a new stake in shares of Inogen in the 4th quarter valued at approximately $48,104,000. New York State Common Retirement Fund lifted its holdings in shares of Inogen by 19.7% in the 1st quarter. New York State Common Retirement Fund now owns 368,575 shares of the medical technology company’s stock valued at $35,151,000 after buying an additional 60,701 shares during the period. Finally, Zevenbergen Capital Investments LLC lifted its holdings in shares of Inogen by 297.7% in the 1st quarter. Zevenbergen Capital Investments LLC now owns 288,503 shares of the medical technology company’s stock valued at $27,514,000 after buying an additional 215,968 shares during the period. Institutional investors own 98.63% of the company’s stock.

Several analysts have recently commented on INGN shares. Stifel Nicolaus raised Protagonist Therapeutics from a “hold” rating to a “buy” rating and raised their price target for the company from $11.00 to $17.00 in a report on Wednesday, May 8th. BidaskClub cut Woodward, Inc.Common Stock from a “strong-buy” rating to a “buy” rating in a report on Saturday. Needham & Company LLC raised Smart Global from a “hold” rating to a “buy” rating and set a $32.00 price target for the company in a report on Friday, June 28th. Finally, JPMorgan Chase & Co. raised their price target on from GBX 385 ($5.03) to GBX 480 ($6.27) and gave the company an “overweight” rating in a report on Wednesday, July 3rd. Three investment analysts have rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $117.60.

INGN stock traded up $1.07 during midday trading on Friday, hitting $61.35. 195,383 shares of the stock were exchanged, compared to its average volume of 338,028. The stock’s 50-day moving average is $65.10. The stock has a market capitalization of $1.32 billion, a PE ratio of 26.67, a price-to-earnings-growth ratio of 2.38 and a beta of 1.45. Inogen Inc has a fifty-two week low of $56.83 and a fifty-two week high of $287.79. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.70 and a current ratio of 7.35.

Inogen (NASDAQ:INGN) last issued its quarterly earnings data on Tuesday, May 7th. The medical technology company reported $0.24 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.05). The firm had revenue of $90.20 million for the quarter, compared to analyst estimates of $89.69 million. Inogen had a return on equity of 15.59% and a net margin of 12.56%. The business’s revenue for the quarter was up 14.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.48 earnings per share. Analysts predict that Inogen Inc will post 1.63 EPS for the current fiscal year.

Inogen Company Profile

Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Read More: Why do analysts give a neutral rating?

Want to see what other hedge funds are holding INGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inogen Inc (NASDAQ:INGN).

Institutional Ownership by Quarter for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.